Blog
Science-backed articles on peptide research, mechanisms, and the latest findings from our research team.
Tirzepatide: Dual GIP/GLP-1 Agonist Profile
Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist that produces unprecedented weight loss results. This comprehensive guide explains its mechanism of action, clinical efficacy, safety profile, and regulatory status.
Survodutide: Dual Agonist Research Overview
Survodutide represents an innovative dual-agonist peptide targeting a distinct hormonal pathway for weight management and metabolic health. This overview covers its mechanisms, clinical research findings, safety profile, and regulatory status within the evolving landscape of multi-agonist therapeutics.
Semaglutide: Complete Pharmacology Guide
Complete pharmacology guide examining semaglutide's mechanisms of action, clinical efficacy data, administration protocols, safety considerations, and regulatory status for diabetes and obesity management.
Retatrutide: Triple Agonist Research Profile
Retatrutide represents the first triple agonist to activate three gut hormone receptors simultaneously. Phase 3 data shows 28.7% weight loss over 68 weeks, significantly exceeding previous obesity trial outcomes.
Pemvidutide: Dual Agonist for NASH Profile
Pemvidutide is a breakthrough dual GLP-1/glucagon agonist showing significant promise for MASH treatment. Learn about its mechanisms, clinical evidence, and regulatory status in this comprehensive guide.
Orforglipron: Oral GLP-1 Agonist Profile
Orforglipron is a breakthrough non-peptide oral GLP-1 agonist designed to provide metabolic benefits without injections or strict timing requirements. This comprehensive profile explores its mechanism of action, clinical efficacy, dosing protocols, and regulatory status.
Mazdutide: GLP-1/Glucagon Dual Agonist
Mazdutide is an investigational dual-agonist peptide activating both GLP-1 and glucagon receptors for obesity management. This guide explores its mechanisms, clinical evidence, safety profile, and regulatory pathway in modern obesity therapeutics.
Lixisenatide: GLP-1 Agonist Profile
Lixisenatide is a short-acting GLP-1 receptor agonist designed for once-daily administration that effectively controls postprandial glucose spikes. This profile covers its pharmacological mechanisms, clinical efficacy data, administration protocols, and comprehensive safety considerations for Type 2 diabetes management.
Liraglutide: GLP-1 Agonist Research Profile
Comprehensive overview of liraglutide, the pioneering GLP-1 agonist approved in 2010. Explores mechanisms of action, extensive clinical evidence supporting cardiovascular and metabolic benefits, safety profile, and how it compares to newer GLP-1 agents like semaglutide and tirzepatide.
Fragment 176-191: HGH Fragment Research
Fragment 176-191 is a truncated growth hormone segment designed to preserve fat-reduction properties while eliminating growth-promoting effects. This guide explores the science, research evidence, mechanisms, and regulatory considerations of this notable research peptide.
Exenatide: First-Generation GLP-1 Profile
Exenatide, discovered from Gila monster venom in 1992, is the first-generation GLP-1 receptor agonist that revolutionized diabetes care. This guide covers its mechanisms of action, clinical efficacy, dosing protocols, and comprehensive safety information for healthcare professionals and researchers.
Dulaglutide: Weekly GLP-1 Agonist Guide
Comprehensive guide to dulaglutide, Eli Lilly's once-weekly GLP-1 receptor agonist. Explore mechanisms, clinical efficacy, dosing protocols, and regulatory status for diabetes management.